Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr

Kiniksa Pharmaceuticals International, plc

Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.
Decision not due to any disagreement with the company on operations, policies, or practices.
Will serve as consultant and special advisor to Science and Research Committee for up to 20 hours/month at $450/hour.
Consulting agreement runs from May 15, 2026 to May 15, 2027, renewable by mutual agreement.
Company reimburses reasonable pre-approved travel and out-of-pocket expenses for consulting services.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eben Tessari

Chief Strategy Officer

Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 01, 2026 23:59 UTC

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the “Company”) of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.

Source: SEC EDGAR

accession 0001730430-26-000021

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.